Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.<ref name="Przuntek_2002">{{cite journal |vauthors=Przuntek H, Bittkau S, Bliesath H |title=Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen |journal=Arch. Neurol. |volume=59 |issue=5 |pages=803–6 |date=May 2002 |pmid=12020263 |doi= 10.1001/archneur.59.5.803|url=http://archneur.ama-assn.org/cgi/pmidlookup?view=long&pmid=12020263|display-authors=etal}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0006899306021494 | title=Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats. | author=Jenny C.E. Owen | author2=Peter S. Whitton | journal=Brain Research |date=October 2006  | volume=1117 | issue=1 | pages=206–212 | doi=10.1016/j.brainres.2006.07.039 | pmid=16996043}}</ref>
